A federal appeals court today rejected a drug industry trade group’s request for all of its appellate judges to reconsider [...] …
Category: Pharma Industry
Arkansas state officials today scheduled a public hearing to enforce the state’s 340B contract pharmacy access law against AstraZeneca, according [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Editors’ note: After publication, Pfizer became the 24th drugmaker to loosen or end its contract pharmacy restrictions for Arkansas covered entities, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Just weeks after passing legislation to prohibit drugmaker 340B contract pharmacy restrictions in the state, Kansas lawmakers voted late Tuesday [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Louisiana’s 340B contract pharmacy access law is constitutional because it governs drug distribution and not pricing, a state official and [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Cosette Pharmaceuticals recently announced refunds to 340B covered entities for 38 medications sold over a year and half. The refunds [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drug manufacturer Bausch Health announced it will exempt all Arkansas providers and pharmacies from its 340B contract pharmacy policy, including [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Japanese drugmaker Takeda recently announced refunds to 340B covered entities for 28 drugs, including one of its top-selling attention-deficit medications. [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Attorneys for both covered entities and drug manufacturers say they expect a significant number of filings to the newly re-established [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Thousands of covered entities that purchased more than one hundred Novartis products between late 2019 and early 2023 will be [...] …